Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Bicalutamide During and After Radiation Improves Progression-Free Survival in Men With Rising PSA Following Primary Surgery for Prostate Cancer

March 23rd 2011

According to primary results of a phase III randomized, placebocontrolled trial reported at the 2011 ASCO Genitourinary Cancers Symposium

New Prostate Cancer Test Yields Promising Results

March 22nd 2011

A recent clinical study reviewed the surprising results of a new prostate cancer test.

Dutasteride Followed By Watchful Waiting May Delay Cancer Progression in Men With Early Prostate Cancer

March 22nd 2011

Dutasteride, a drug commonly used to treat benign prostatic hyperplasia, may also be useful as part of a "watchful waiting" strategy

Study Presents Preliminary But Impressive Data In Metastatic Castration- Resistant Prostate Cancer

March 21st 2011

cabozantinib (XL184) - a novel wide-spectrum tyrosine kinase inhibitor (TKI) - achieved dramatic results in patients with castration-resistant prostate cancer

Excessive multivitamin consumption may be linked to prostate cancer

March 16th 2011

Though taking multivitamins has been linked to potential health benefits, a new study has found that an excessive consumption of multivitamins may not be beneficial.

Exercise Routine Recommended for Prostate Cancer Survivors

March 14th 2011

Researchers are calling for prostate cancer survivors to incorporate physical activity into their daily routine.

Dr. Alter on 2011 ASCO GU Prostate Cancer Findings

March 14th 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

Advisory Panel Discusses Expanded Indication for Avodart

March 9th 2011

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

Long Ring Finger = Less Prostate Cancer?

March 9th 2011

According to the British Journal of Cancer, a new study by London's Institute of Cancer Research finds that finger length might be an indicator of prostate cancer risk.

Novel Agents in the Management of Castration-Resistant Metastatic Prostate Cancer

March 4th 2011

The Prostate Cancer Clinical States model was first proposed by Scher and colleagues nearly 10 years ago.

Behavioral Therapy Alleviates Prostatectomy-Induced Incontinence

March 4th 2011

Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.

Managing the Side Effects of Androgen-Deprivation Therapy

March 4th 2011

Androgen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.

Jevtana Approved for Advanced Prostate Cancer

March 4th 2011

The FDA approved the injectable drug Jevtana (cabazitaxel), a microtubule inhibitor, in combination with prednisone as a second-line therapy for men with advanced castrate-resistant prostate cancer

Abiraterone Praised as a Significant Advance in Metastatic Prostate Cancer

March 4th 2011

Data presented at the recent 35th European Society for Medical Oncology Congress in Milan, Italy, showed a significant survival advantage for men with advanced metastatic castration resistant prostate cancer (CRPC) who received abiraterone acetate compared with placebo.

Can Pomegranate Juice Prevent Metastasis?

March 2nd 2011

University of California researchers reported that prostate cancer cells subjected to pomegranate juice did not metastasize as readily as untreated prostate cancer cells.

Men With Prostate Cancer Should Exercise

March 2nd 2011

Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week

Immunotherapy

August 16th 2010

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

BIO-BUZZ: QUADRAMETï¿½: A New Option for Hormone-Refractory Prostate Cancer?

August 16th 2010

The treatment of hormone-refractory prostate cancer often represents a therapeutic challenge. As the most common malignancy in men and the second-leading cause of cancer death in the US, the number of patients requiring posthormonal therapy is increasing.

The Rapid Reporter: April 2007

August 13th 2010

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).

AUA Updates Prostate Cancer Guidelines

July 12th 2010

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.